With $2.4M Grant, Researchers to Collaborate in Study of Heart Disease
After receiving a five-year, $2.4 million grant from the National Institute of Environmental Health Sciences (NIEHS), two University of Cincinnati researchers will collaborate on an investigation of gene-environment interactions during embryonic development and their consequences in adult heart disease.
Alvaro Puga, PhD, of the Department of Environmental Health, and Jack Rubinstein, MD, of the Department of Internal Medicine, Division of Cardiovascular Health and Disease, received the grant from the NIEHS, an institute of the National Institutes of Health (NIH). They will serve as co-principal investigators.
The grant will enable them to study connections between the bodys Ah receptor (AHR) gene, fetal exposure to dioxin and cardiovascular disease. Using mice, they will test the hypothesis that exposure to dioxin during pregnancy redirects AHR functions toward toxic and/or adaptive responses that can lead to adult cardiovascular disease.
"The basic idea of our research is that there is a developmental origin of heart disease, says Puga, who has studied environmental toxins extensively as a faculty member in the environmental health departments Division of Environmental Genetics and Molecular Toxicology. He is also an associate director of UCs Center for Environmental Genetics, which is funded by NIEHS and housed in the environmental health department under the direction of Shuk-mei Ho, PhD, Jacob G. Schmidlapp Professor and Chair of Environmental Health.
Dioxins are highly toxic compounds that are byproducts of industrial processes and are present in the environment. They are ingested into the body orally, Puga says (through eating the meat of cows that have grazed on dioxin-contaminated fields, for example), and stored in fat. Dioxin can be mobilized during pregnancy when fat stores are needed, he says.
Rubinstein says researchers will use a sophisticated high-frequency ultrasound imaging machine to study mice that have been exposed to dioxin, beginning in the womb.
"We can actually measure the heart function and see the structure of the heart before the litters are born, he says. "So well be able to follow the litters from before birth all the way out after birth and into adulthood.
Adds Puga: "Congenital cardiovascular malformations are the leading cause of neonatal and infant death and a major cause of adult cardiac insufficiency, and theres a critical need to understand the mechanisms that causes these diseases.
"This study will establish the role of AHR in cardiac development and help identify gene-environment interactions that may aggravate heart disease susceptibility.
The collaboration between Rubinstein and Puga was initiated by Vinicius Carreira, a graduate student in the Puga lab and a doctor of veterinary medicine and animal pathologist, who was interested in this project for his doctoral thesis and contacted Rubinstein with the idea.
"His involvement in the project illustrates how critically important the role our graduate students play is in the research done in the College of Medicine, Puga says.
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.